Related Experiment Video

Updated: Jun 18, 2026

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors
09:04

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors

Published on: March 15, 2016

Management of vascular endothelial growth factor and multikinase inhibitor side effects

Laura S Wood1

  • 1Cleveland Clinic Taussig Cancer Institute, Ohio, USA.

Clinical Journal of Oncology Nursing
|December 2, 2009
PubMed

Insights

Nurses manage side effects from multikinase inhibitors (MKIs) for advanced kidney cancer. This case study details strategies to improve treatment adherence for patients receiving these targeted therapies.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Advanced kidney cancer treatment has improved with vascular endothelial growth factor and multikinase inhibitors (MKIs).
  • MKIs can cause significant side effects, including dermatologic, gastrointestinal, hematologic, and metabolic toxicities.
  • These toxicities may negatively impact patient adherence to treatment regimens.

Observation:

  • Nurses are crucial in managing adverse events associated with novel cancer therapies.
  • A case study approach is utilized to explore practical side-effect management.
  • Focus is on patients undergoing treatment for advanced renal cell carcinoma with MKIs.

Findings:

  • Effective side-effect management is essential for maintaining treatment continuity.
  • Proactive nursing interventions can mitigate the impact of MKI-associated toxicities.
  • Strategies discussed aim to enhance patient quality of life and treatment outcomes.

Implications:

  • This case study provides valuable insights for healthcare professionals managing patients on MKIs.
  • Implementing targeted nursing strategies can improve treatment adherence and patient outcomes.
  • Further research into optimizing supportive care for MKI therapy is warranted.

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...